Home » Stocks » PULM

Pulmatrix, Inc. (PULM)

Stock Price: $1.28 USD 0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $1.30 +0.02 (1.56%) Nov 27, 3:46 PM

Stock Price Chart

Key Info

Market Cap 44.04M
Revenue (ttm) 12.32M
Net Income (ttm) -20.45M
Shares Out 34.41M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $1.28
Previous Close $1.28
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.29
Day's Range 1.24 - 1.30
Day's Volume 323,984
52-Week Range 0.78 - 2.06

More Stats

Market Cap 44.04M
Enterprise Value 11.43M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 34.41M
Float n/a
EPS (basic) -0.75
EPS (diluted) -0.83
FCF / Share -0.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 90,785
Short Ratio 0.20
Short % of Float n/a
Beta 1.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.58
PB Ratio 1.87
Revenue 12.32M
Operating Income -11.10M
Net Income -20.45M
Free Cash Flow -14.36M
Net Cash 32.61M
Net Cash / Share 0.95
Gross Margin -40.06%
Operating Margin -90.10%
Profit Margin -166.00%
FCF Margin -116.53%
ROA -18.62%
ROE -107.00%
ROIC 243.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $1.28
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth5069.93%-54.33%-59.88%-30.47%241.19%--
Gross Profit7.910.150.340.841.200.35-
Operating Income-20.69-20.40-17.48-24.87-23.02-9.08-0.52
Net Income-20.60-20.56-18.06-27.84-26.17-6.45-0.52
Shares Outstanding16.734.131.941.480.810.020.08
Earnings Per Share-1.23-4.98-9.32-18.80-32.30-345.20-6.50
Operating Cash Flow3.23-16.76-14.48-13.24-12.47-9.17-0.43
Capital Expenditures-0.06-0.02-0.07-0.43-0.27-0.29-
Free Cash Flow3.17-16.78-14.55-13.67-12.74-9.45-0.43
Cash & Equivalents23.442.563.554.1818.900.450.10
Total Debt0.68-3.225.806.7239.70-
Net Cash / Debt22.772.560.33-1.6212.18-39.250.10
Book Value11.0211.8410.148.7632.61-78.790.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pulmatrix, Inc.
Country United States
Employees 22
CEO Teofilo Raad

Stock Information

Ticker Symbol PULM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PULM


Pulmatrix, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.